Effectiveness of hepatitis A vaccination among people living with HIV in Taiwan: Is one dose enough?
Background: Single dose hepatitis A virus (HAV) vaccine had been proven its efficacy in immunocompetent but not immunocompromised hosts. We aim to investigate the effectiveness of one dose versus 2 doses HAV vaccine among people living with HIV (PLHIV). Method: We conducted a 1:1 single center retro...
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2022-02-01
|
| Series: | Journal of Microbiology, Immunology and Infection |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S1684118220301559 |
| _version_ | 1818974813116432384 |
|---|---|
| author | Pei-Hsuan Tsai Mao-Song Tsai Ying-Hsuan Chiang Chung-Yu Shih Chia-Ying Liu Yu-Chung Chuang Chia-Jui Yang |
| author_facet | Pei-Hsuan Tsai Mao-Song Tsai Ying-Hsuan Chiang Chung-Yu Shih Chia-Ying Liu Yu-Chung Chuang Chia-Jui Yang |
| author_sort | Pei-Hsuan Tsai |
| collection | DOAJ |
| description | Background: Single dose hepatitis A virus (HAV) vaccine had been proven its efficacy in immunocompetent but not immunocompromised hosts. We aim to investigate the effectiveness of one dose versus 2 doses HAV vaccine among people living with HIV (PLHIV). Method: We conducted a 1:1 single center retrospective case–control study for PLHIV in Northern Taiwan. Case patients were those who received single dose HAV vaccine and controls were those who completed standard 2 doses HAV vaccine. Nationwide campaign of single dose HAV vaccine had been practiced for high risk population including PLHIV and those who had newly diagnosed sexually transmitted diseases. Results: During February 2016 and December 2017, 90 cases received single dose HAV vaccine provided while the other 90 age-matched controls received 2 doses vaccine were enrolled. We found more injection drug users (22.22% vs. 1.11%, p < 0.0001), more co-infection with viral hepatitis C (28.89% vs. 5.56%, p < 0.0001), and history of syphilis infection (56.67% VS 30%, p = 0.0003) in single dose group than 2 doses group. Seroconversion rate at one year was significantly higher in 2 doses group (97.78% vs 56.67%, p < 0.0001). Among single dose group, people with hepatitis B or C virus co-infection (HBV: p = 0.02, aOR: 0.03, 95% CI: 0.002–0.55; HCV: p = 0.002, aOR: 0.22, 95% CI: 0.08–0.58) were less likely to achieve seropositivity, while those who had higher CD4 count at baseline and one year, had better response to vaccine. Conclusion: Two doses HAV vaccine is necessary among PLHIV to achieve sustained seroresponse rather than single dose. |
| first_indexed | 2024-12-20T15:46:01Z |
| format | Article |
| id | doaj.art-ea192d84cf2e4f6a8c0013b312357b45 |
| institution | Directory Open Access Journal |
| issn | 1684-1182 |
| language | English |
| last_indexed | 2024-12-20T15:46:01Z |
| publishDate | 2022-02-01 |
| publisher | Elsevier |
| record_format | Article |
| series | Journal of Microbiology, Immunology and Infection |
| spelling | doaj.art-ea192d84cf2e4f6a8c0013b312357b452022-12-21T19:34:58ZengElsevierJournal of Microbiology, Immunology and Infection1684-11822022-02-015511825Effectiveness of hepatitis A vaccination among people living with HIV in Taiwan: Is one dose enough?Pei-Hsuan Tsai0Mao-Song Tsai1Ying-Hsuan Chiang2Chung-Yu Shih3Chia-Ying Liu4Yu-Chung Chuang5Chia-Jui Yang6Department of Internal Medicine, Far Eastern Memorial Hospital, New Taipei City, TaiwanDepartment of Internal Medicine, Far Eastern Memorial Hospital, New Taipei City, Taiwan; School of Medicine, Fu Jen Catholic University, New Taipei City, TaiwanDepartment of Internal Medicine, Far Eastern Memorial Hospital, New Taipei City, TaiwanDepartment of Internal Medicine, Far Eastern Memorial Hospital, New Taipei City, TaiwanDepartment of Internal Medicine, Far Eastern Memorial Hospital, New Taipei City, TaiwanDepartment of Internal Medicine, National Taiwan University Hospital, Taipei City, TaiwanDepartment of Internal Medicine, Far Eastern Memorial Hospital, New Taipei City, Taiwan; School of Medicine, National Yang-Ming University, Taipei City, Taiwan; Corresponding author. Department of Internal Medicine, Far Eastern Memorial Hospital, No.21, Sec. 2, Nanya S. Rd., Banciao Dist., New Taipei City, 220, Taiwan. Fax: +886-2-77281321.Background: Single dose hepatitis A virus (HAV) vaccine had been proven its efficacy in immunocompetent but not immunocompromised hosts. We aim to investigate the effectiveness of one dose versus 2 doses HAV vaccine among people living with HIV (PLHIV). Method: We conducted a 1:1 single center retrospective case–control study for PLHIV in Northern Taiwan. Case patients were those who received single dose HAV vaccine and controls were those who completed standard 2 doses HAV vaccine. Nationwide campaign of single dose HAV vaccine had been practiced for high risk population including PLHIV and those who had newly diagnosed sexually transmitted diseases. Results: During February 2016 and December 2017, 90 cases received single dose HAV vaccine provided while the other 90 age-matched controls received 2 doses vaccine were enrolled. We found more injection drug users (22.22% vs. 1.11%, p < 0.0001), more co-infection with viral hepatitis C (28.89% vs. 5.56%, p < 0.0001), and history of syphilis infection (56.67% VS 30%, p = 0.0003) in single dose group than 2 doses group. Seroconversion rate at one year was significantly higher in 2 doses group (97.78% vs 56.67%, p < 0.0001). Among single dose group, people with hepatitis B or C virus co-infection (HBV: p = 0.02, aOR: 0.03, 95% CI: 0.002–0.55; HCV: p = 0.002, aOR: 0.22, 95% CI: 0.08–0.58) were less likely to achieve seropositivity, while those who had higher CD4 count at baseline and one year, had better response to vaccine. Conclusion: Two doses HAV vaccine is necessary among PLHIV to achieve sustained seroresponse rather than single dose.http://www.sciencedirect.com/science/article/pii/S1684118220301559Acute hepatitis AImmunizationImmunogenicityHuman immunodeficiency virus |
| spellingShingle | Pei-Hsuan Tsai Mao-Song Tsai Ying-Hsuan Chiang Chung-Yu Shih Chia-Ying Liu Yu-Chung Chuang Chia-Jui Yang Effectiveness of hepatitis A vaccination among people living with HIV in Taiwan: Is one dose enough? Journal of Microbiology, Immunology and Infection Acute hepatitis A Immunization Immunogenicity Human immunodeficiency virus |
| title | Effectiveness of hepatitis A vaccination among people living with HIV in Taiwan: Is one dose enough? |
| title_full | Effectiveness of hepatitis A vaccination among people living with HIV in Taiwan: Is one dose enough? |
| title_fullStr | Effectiveness of hepatitis A vaccination among people living with HIV in Taiwan: Is one dose enough? |
| title_full_unstemmed | Effectiveness of hepatitis A vaccination among people living with HIV in Taiwan: Is one dose enough? |
| title_short | Effectiveness of hepatitis A vaccination among people living with HIV in Taiwan: Is one dose enough? |
| title_sort | effectiveness of hepatitis a vaccination among people living with hiv in taiwan is one dose enough |
| topic | Acute hepatitis A Immunization Immunogenicity Human immunodeficiency virus |
| url | http://www.sciencedirect.com/science/article/pii/S1684118220301559 |
| work_keys_str_mv | AT peihsuantsai effectivenessofhepatitisavaccinationamongpeoplelivingwithhivintaiwanisonedoseenough AT maosongtsai effectivenessofhepatitisavaccinationamongpeoplelivingwithhivintaiwanisonedoseenough AT yinghsuanchiang effectivenessofhepatitisavaccinationamongpeoplelivingwithhivintaiwanisonedoseenough AT chungyushih effectivenessofhepatitisavaccinationamongpeoplelivingwithhivintaiwanisonedoseenough AT chiayingliu effectivenessofhepatitisavaccinationamongpeoplelivingwithhivintaiwanisonedoseenough AT yuchungchuang effectivenessofhepatitisavaccinationamongpeoplelivingwithhivintaiwanisonedoseenough AT chiajuiyang effectivenessofhepatitisavaccinationamongpeoplelivingwithhivintaiwanisonedoseenough |